Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Cancer Survivors Found to Be at Greater Risk of Frailty-Related Bone Fractures

November 18, 2022
By Nicholas Wrigley
Article

Factors such as chemotherapy treatment and a cancer diagnosis within the past 5 years were associated with a greater risk of frailty-related bone fractures among older cancer survivors, according to findings from a recent cohort study.

Cancer survivors have a significantly higher risk of frailty-related bone fractures for several years after diagnosis vs those without a history of cancer, according to findings from a recent study published in JAMA Oncology.

Older adults with a history of cancer were found to have a 57% greater risk of fractures in the first year after diagnosis (HR 1.57; 95% CI, 1.38-1.79) vs those without. The risk was especially elevated for those diagnosed with distant metastases 1 to 4 years prior to the study (HR 2.12; 95% CI, 1.75-2.58). This disparity in risk derived largely from vertebral (HR 2.46; 95% CI, 1.93-3.13) and pelvic (HR, 2.46; 95% CI 1.84-3.29) fractures. The risk of radial fracture meanwhile did not substantially vary based on history of cancer (HR 1.09; 95% CI, 0.64-1.87).

“Cancer survivors are at higher risk of bone fractures likely because of higher rates of osteoporosis coupled with low muscle mass, poor balance, and unexpected changes in gait,” the investigators wrote. “One novel finding in this study was the difference in risk by fracture site….[It] is important to understand the differences in risk by fracture site because each fracture type is associated with certain health care costs and risks of subsequent morbidity and mortality. Pelvic fractures, in particular, are highly associated with further health issues, including mortality, and account for nearly 77% of all costs incurred from incident fractures.”

Other relevant risk factors included treatment modality, lifestyle, and sex. Survivors of cancer who received chemotherapy were 31% more likely to have a fracture vs those who didn’t receive chemotherapy (HR 1.31; 95% CI, 1.09-1.57) in the first 4 years after diagnosis and 22% more likely 5 or more years beyond diagnosis (HR 1.22; 95% CI, 0.99-1.51). Additionally, survivors who were current smokers at the time of the study were more than twice as likely to have fractures (HR 2.27; 95% CI, 1.55-3.33) as those who never smoked. The risk of fracture was lower among physically active survivors 5 or more years after diagnosis (HR 0.76; 95% CI, 0.54-1.07), but this correlation was not statistically significant. Higher BMI (≥25) was also associated with lower risk of fracture for those with (HR 0.72; 95% CI, 0.62-0.85) and without (HR 0.78; 95% CI, 0.75-0.81) a history of cancer. Men were generally less likely to experience fractures than women, including in those without a history of cancer (HR 0.51; 95% CI, 0.48-0.54), in survivors 1 to 4 years after diagnosis (HR 0.53; 95% CI, 0.41-0.69), and in survivors 5 or more years beyond (HR, 0.74; 95% CI, 0.54-1.01), though the latter correlation was not statistically significant.

This longitudinal cohort study examined 92,413 eligible participants out of 116,355 adults who completed the 1999 Cancer Prevention Study II Nutrition Cohort survey and were linked with Medicare claims from 1999 to 2017. The vast majority of this study population were White (97.9%) and older than 60 years (95.8%) at the time of the survey. The median age was 69.4 years, and most participants were women (56%). Most either met (24.1%) or significantly exceeded (32.3%) the guidelines for moderate to vigorous physical activity, and most (54.2%) had a BMI of 25 or greater. Current smokers comprised 4.7% of the population, with former smokers comprising a further 48.6%.

Incident fractures affected 12,943 participants in total. The primary analysis only included first fractures because roughly 4% (n = 3793) of participants experienced more than one; further exploratory analyses assessed the risks related to multiple fractures.

“Future studies are needed that explore the associations of [moderate- to vigorous-intensity physical activity], strength training, smoking, alcohol use, or diet quality across the life course, both before and after diagnosis, with fracture risk in [survivors of cancer],” the investigators concluded, writing nonetheless that “[these] survivors, especially those who received chemotherapy or received a cancer diagnosis more recently (<5 years), may benefit from clinical guidance on frailty-related fracture prevention.”

Reference

Rees-Punia E, Newton CC, Parsons HM, et al. Fracture risk among older cancer survivors compared with older adults without a history of cancer. JAMA Oncol. Published online November 3, 2022. doi:10.1001/jamaoncol.2022.5153

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Physical therapists may play a key role in patient care before, during, and after treatment for cancer, according to Alison Ankiewicz, PT, DPT.
Related Content
Advertisement

The denosumab-bmwo products Stoboclo and Osenvelt have been approved as interchangeable with the denosumab products Prolia and Xgeva, respectively.

FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars

Tim Cortese
November 1st 2025
Article

The denosumab-bmwo products Stoboclo and Osenvelt have been approved as interchangeable with the denosumab products Prolia and Xgeva, respectively.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


A unique cisplatin-containing intratumoral formulation achieved a median OS of 18.7 months in patients who were dosed at 40% or more of their TTB.

Novel Intratumoral Formulation Shows Responses/Safety in Metastatic Cancers

Tim Cortese
October 31st 2025
Article

A unique cisplatin-containing intratumoral formulation achieved a median OS of 18.7 months in patients who were dosed at 40% or more of their TTB.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Site Logo

Career Stage and Location Found to Impact Oncology Coverage in the US

Ariana Pelosci
October 30th 2025
Article

Rural populations and those with higher cancer burden and socioeconomic risk were found to have gaps in oncology care across the US.


Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.

ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma

Russ Conroy
October 29th 2025
Article

Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.

Related Content
Advertisement

The denosumab-bmwo products Stoboclo and Osenvelt have been approved as interchangeable with the denosumab products Prolia and Xgeva, respectively.

FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars

Tim Cortese
November 1st 2025
Article

The denosumab-bmwo products Stoboclo and Osenvelt have been approved as interchangeable with the denosumab products Prolia and Xgeva, respectively.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


A unique cisplatin-containing intratumoral formulation achieved a median OS of 18.7 months in patients who were dosed at 40% or more of their TTB.

Novel Intratumoral Formulation Shows Responses/Safety in Metastatic Cancers

Tim Cortese
October 31st 2025
Article

A unique cisplatin-containing intratumoral formulation achieved a median OS of 18.7 months in patients who were dosed at 40% or more of their TTB.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Site Logo

Career Stage and Location Found to Impact Oncology Coverage in the US

Ariana Pelosci
October 30th 2025
Article

Rural populations and those with higher cancer burden and socioeconomic risk were found to have gaps in oncology care across the US.


Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.

ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma

Russ Conroy
October 29th 2025
Article

Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.